InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Warner-Lambert still in Swiss-type pain in the UK

Kingsley Egbuonu, London


Following the guidance from the Court of Appeal, Mr Justice Arnold has ruled that some of the claims of Warner-Lambert's second medical use patent for the drug pregabalin are invalid, and that Actavis has not infringed two claims directed to the use of pregabalin

Background Warner-Lambert marketed, through Pfizer, the drug pregabalin under the trade mark Lyrica for the treatment of epilepsy, generalised anxiety disorder (non-patented indications) and neuropathic pain. The basic patent protection (European Patent No. 0 641 330), supplementary protection certificate (SPC/GB04/034) and...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain FREE access to up to five free articles when you register now.

Join here

More from the Managing IP blog


null null null

nullnullnull

null

May / June 2019

From trademarks to trade secrets: in-house tips on brand protection in China

Despite the well-known struggles in protecting trademarks and trade secrets in China, there are some tried-and-tested strategies to employ, as Karry Lai and Ellie Mertens hear from in-house counsel at a range of domestic and international companies



Most read articles

Supplements